title: Clinical analysis of cataract surgery complicated by endophthalmitis.
abstract: OBJECTIVE
  To assess the efficacy of vitrectomy combined with intravitreal injection in the treatment of endophthalmitis after phacoemulsification and IOL implantation.
  
  
  METHODS
  Five patients (5 eyes), who had undergone conventional phacoemulsification combined with IOL implantation at another treatment facility, presented with endophthalmitis. The subjects ranged in age from 41 to 79 years (65.8 ± 0.5 years on average), and three were male. All five cases received bacterial culture susceptibility testing. On the basis of the treatment of primary disease, 3 cases had anterior chamber irrigation, and posterior vitrectomy followed by intravitreal injection of 1 mg vancomycin plus 2.25 mg ceftazidime.
  
  
  RESULTS
  Four out of the five cases of endophthalmitis had a positive bacterial culture testing results (two cases of staphylococcus epidermidis, one case of enterococcus faecalis and one case of head-like staphylococcus), and the remaining case had no bacterial growth. Four cases showed restored visual acuity, clear vitreous cavity, and no retinal detachment or other complications.
  
  
  CONCLUSIONS
  Management of patients presenting with endophthalmitis subsequent to cataract surgery should include: prompt bacterial culture and drug sensitivity tests, and where appropriate, vitrectomy combined with intravitreal injection of vancomycin.
authors.affiliation: Department of Ophthalmology, The First Affiliated Hispital of Chinese PLA General Hospital, Beijing 100038, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Zhu
authors.forename: Yuli
authors.initials: Y
authors.lastname: Pi
authors.forename: Qing
authors.initials: Q
authors.lastname: Guo
authors.forename: Zhaohui
authors.initials: Z
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002442:Ceftazidime / Q000008:administration & dosage; D009877:Endophthalmitis / Q000209:etiology*; D015818:Eye Infections, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D019654:Lens Implantation, Intraocular / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification / Q000009:adverse effects*; D012189:Retrospective Studies; D013210:Staphylococcus / Q000302:isolation & purification; D013212:Staphylococcus epidermidis / Q000302:isolation & purification; D014640:Vancomycin / Q000008:administration & dosage; D014792:Visual Acuity; D014821:Vitrectomy; D014822:Vitreous Body
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin; D002442:Ceftazidime